Hampstead, MD, United States of America

Paul Ernest Goldenbaum

This inventor holds 6 USPTO granted patents and 1 EPO patent. Top assignee: Becton Dickinson and Company Limited. Active years: 1991-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Ernest Goldenbaum. Retrieved from https://idiyas.com/inventor/paul-ernest-goldenbaum

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 74(Granted Patents)


Location History:

  • Towson, MD (US) (1991)
  • Hampstead., MD (US) (2002)
  • Hampstead, MD (US) (2000 - 2010)

Company Filing History:


Years Active: 1991-2010

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Paul Ernest Goldenbaum: Innovator in Sepsis Diagnosis

Introduction

Paul Ernest Goldenbaum is a notable inventor based in Hampstead, MD (US). He has made significant contributions to the field of medical diagnostics, particularly in the early detection of sepsis. With a total of 6 patents to his name, Goldenbaum's work has the potential to save countless lives by enabling timely clinical interventions.

Latest Patents

Goldenbaum's latest patents focus on innovative methods for diagnosing sepsis and Systemic Inflammatory Response Syndrome (SIRS) using biomarker profiles. One of his key inventions involves a molecular diagnostics approach that allows for the early prediction or diagnosis of sepsis. This method compares an individual's biomarker expression profile to those of control populations, facilitating the diagnosis of sepsis from a single bodily fluid sample. This approach eliminates the need for prolonged patient monitoring, allowing for immediate clinical intervention before severe symptoms develop.

Another significant patent involves mass spectrometry techniques for determining an individual's sepsis status. This method utilizes a biomarker profile obtained from a biological sample and compares it to a reference profile. The comparison classifies the individual as belonging to a reference population, thus determining their sepsis status without needing to identify specific biomarkers.

Career Highlights

Goldenbaum is currently associated with Becton Dickinson and Company Limited, where he continues to advance his research in medical diagnostics. His work has garnered attention for its innovative approach to addressing critical health issues.

Collaborations

Throughout his career, Goldenbaum has collaborated with esteemed colleagues, including Gregory Tice and Richard Ivey. These partnerships have contributed to the development and refinement of his groundbreaking diagnostic techniques.

Conclusion

Paul Ernest Goldenbaum's contributions to the field of sepsis diagnosis exemplify the impact of innovation in healthcare. His patents not only enhance early detection methods but also pave the way for improved patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…